Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)

Market Cap	43.74B
Revenue (ttm)	954.64M
Net Income (ttm)	-231.66M
Shares Out	919.06M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,454,743
Average Volume	37,651,336
Open	50.89
Previous Close	47.58
Day's Range	45.51 - 50.89
52-Week Range	9.71 - 60.79
Beta	0.16
RSI	49.31
Earnings Date	Aug 23, 2025

About SHE:300255

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. It offers crude heparin sodium, heparin sodium raw materials, heparin sodium injections, low molecular weight heparin calcium raw materials and injections, enoxaparin sodium raw materials and injections, nadri heparin calcium API, nandroparin calcium injection, and dalteparin ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 1,254
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300255

Financial Performance

In 2024, SHE:300255's revenue was 1.03 billion, a decrease of -26.92% compared to the previous year's 1.41 billion. Losses were -249.48 million, -79.88% less than in 2023.